A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

A Fibroblast-Based Adenoviral Reporter System Driven by the Mouse Collagen Type I Alpha 1 Promoter for Antifibrotic Drug Screening

116 views

⸱

DOI:

10.3791/71678

⸱

August 14th, 2026

* These authors contributed equally

In This Article

Summary

This protocol describes the development of a fibroblast-based adenoviral reporter system driven by a mouse type I collagen promoter to enable longitudinal monitoring of fibroblast activation and facilitate high-throughput screening of antifibrotic compounds.

Abstract

Cardiac fibrosis, characterized by aberrant fibroblast activation and excessive extracellular matrix deposition, lacks target-specific therapies, largely due to the absence of longitudinal, scalable, and non-destructive in vitro screening platforms. Traditional end-point assays and resource-intensive stem cell models inherently preclude real-time monitoring of fibrotic progression. To overcome these limitations, this protocol describes the generation, optimization, and validation of a mouse collagen type I alpha 1 (Col1a1) promoter-driven adenoviral mCherry fluorescent reporter system (Ad-mCol1a1p-mCherry) in NIH/3T3 fibroblasts. The critical steps for recombinant adenovirus packaging, transduction optimization (multiplicity of infection) to minimize cytotoxicity, and the establishment of a robust transforming growth factor beta (TGF-β)-induced fibrosis model are detailed. By circumventing the need for cell fixation, this system enables direct and longitudinal monitoring of collagen transcription in live cells. The model’s specificity and reliability are pharmacologically validated using the TGF‑β type I receptor (ALK5) inhibitor SB431542, with fluorescent readouts correlating with endogenous fibrotic markers quantified via reverse transcription quantitative polymerase chain reaction and enzyme-linked immunosorbent assay. Ultimately, this cost-effective platform provides an accessible tool for the high-throughput screening of novel antifibrotic agents, thereby accelerating translational cardiovascular research.

Introduction

The management of cardiac fibrosis presents significant clinical challenges. Characterized by the aberrant activation of quiescent fibroblasts into myofibroblasts and excessive extracellular matrix (ECM) deposition, it represents an irreversible terminal pathway shared by heart failure, myocardial infarction, and other cardiovascular diseases1,2,3. However, current treatment strategies face significant limitations. Conventional interventions—such as diuretics, β-blockers, and renin–angiotensin–aldosterone system inhibitors—primarily alleviate syst....

Access restricted. Please log in or start a trial to view this content.

Protocol

We confirm that all experiments were performed in accordance with institutional and national guidelines. Because this study exclusively utilized the established NIH Swiss mouse embryo fibroblast cell line (NIH/3T3) and the mCol1a1p-mCherry reporter system, and did not involve any vertebrate animals, embryos, or human subjects, ethical approval from an institutional review board was not required for the procedures described in this manuscript.

All procedures involving recombinant adenoviral vectors were conducted in accordance with institutional biosafety regulations and standard Biosafety Level 2 (BSL-2) practices. Viral h....

Access restricted. Please log in or start a trial to view this content.

Results

A schematic overview of the construction and packaging of the mCol1a1p-mCherry recombinant adenovirus is shown in Figure 1A. The mouse Col1a1 promoter was cloned upstream of the mCherry reporter gene and incorporated into an adenoviral vector, followed by viral packaging and amplification in HEK293 cells. The workflow illustrates key experimental steps, including viral infection, fibrotic stimulation, pharmacological intervention, and fluorescence-based si.......

Access restricted. Please log in or start a trial to view this content.

Discussion

Cardiac fibrosis contributes to the progression of heart failure, and the development of effective antifibrotic therapies is limited by the lack of longitudinal screening platforms2,13. Conventional methods for evaluating antifibrotic efficacy, including Western blotting, RT-qPCR, and immunofluorescence staining, rely on endpoint measurements that require cell lysis or fixation. These approaches prevent real-time monitoring of fibrotic progression in living cells.......

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors have no conflicts of interest to disclose.

Acknowledgements

This work was supported by grants from the National Natural Science Foundation of China (32371158 to H.X.), National Key R&D Program (2023YFA1800902 to H.X.), "Tianchi Talent" program, Open Project of the National Key Laboratory of Vascular Homeostasis and Remodeling (Peking University) (202404 to R.Z; 202403 to Y.M.W.), Open Project of the Key Laboratory of Xinjiang Endemic and Ethnic Diseases, Ministry of Education (Peking University) (KF202404 to H.X.).

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
384-Well Glass-Bottom MicroplateCellvis, USAP384-1.5H-N384-well glass-bottom plate used for cell seeding, viral infection, staining, and fluorescence imaging.
Adenoviral Backbone PlasmidMicrobix, CanadapBHGloxΔE1,3CrePlasmid used to generate the full-length recombinant adenoviral genome.
Adenoviral Shuttle Vector: pDC315-mCol1a1p-mCherryGeneChem, ChinaCustom serviceRecombinant adenoviral shuttle vector containing the 2354 bp mouse Col1a1 promoter driving mCherry expression.
Benzonase NucleaseMerck Millipore, USA70664-3Endonuclease used during adenoviral purification to remove contaminating nucleic acids.
Biological Safety Cabinet (Class II)Esco Lifesciences Group, SingaporeAC2-4S1Certified biosafety cabinet used for recombinant adenoviral handling and sterile cell culture procedures.
Cell Culture Medium (Complete DMEM/F12)HyClone, USA12800-017Complete culture medium used for NIH/3T3 and HEK293 cell maintenance.
CellPathfinder Image Analysis SoftwareYokogawa Electric Corporation, JapanVersion 3.08.01Image-analysis software used for automated fluorescence quantification and cell segmentation.
CellVoyager CV8000 High-Content Screening SystemYokogawa Electric Corporation, JapanCV8000High-content imaging system used for mCherry and Hoechst fluorescence acquisition.
CO2 Cell Culture IncubatorThermo Fisher Scientific, USA3111Humidified incubator maintained at 37 °C with 5% CO2 for mammalian cell culture.
Dimethyl Sulfoxide (DMSO)Sigma-Aldrich, USAD2650Solvent used for SB431542 preparation.
Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F-12)Servicebio, ChinaG4610Basal culture medium used for NIH/3T3 fibroblasts.
Fetal Bovine Serum (FBS)Ausbian, AustraliaVS500TSerum supplement used at 10% (v/v) for complete culture medium preparation.
Hoechst 33342 Fluorescent StainInvitrogen, USAH3570Nuclear stain used for fluorescence imaging and nuclear count normalization.
HEK293 CellsATCC, USACRL-1573Packaging cell line used for adenoviral production and amplification.
Human Recombinant TGF-β1MedChemExpress, ChinaHY-P78214Cytokine used to induce fibrotic activation in NIH/3T3 fibroblasts.
Image Acquisition SoftwareYokogawa Electric Corporation, JapanVersion 3.08.01.03Software used for automated fluorescence image acquisition and microscope control.
Lipid-Based Transfection ReagentInvitrogen, USA11668-019Transfection reagent used for adenoviral plasmid delivery into HEK293 cells.
Microcentrifuge TubesAxygen, USAMCT-150-CTubes used for RNA lysate storage and sample processing.
Microplate ReaderTecan, SwitzerlandSparkMultimode microplate reader used for ELISA absorbance measurements.
Mouse Type I Collagen ELISA KitMeike Biotechnology, ChinaMK6778AELISA kit used to quantify secreted type I collagen in culture supernatants.
NIH/3T3 Mouse FibroblastsProcell Life Science, ChinaCL-0171Mouse fibroblast cell line used for reporter model establishment and validation.
PacI Restriction EnzymeNew England Biolabs, USAR0547SRestriction enzyme used for adenoviral plasmid linearization.
Penicillin–Streptomycin SolutionGibco, USA15140-122Antibiotic solution supplemented at 1% (v/v) to prevent bacterial contamination.
PerfectStart Green qPCR SuperMixTransGen Biotech, ChinaAQ602SYBR Green-based qPCR master mix used for quantitative PCR analysis.
Phosphate-Buffered Saline (PBS)Servicebio, ChinaG4202Buffer used for washing cells and reagent preparation.
pDC315-EGFP Shuttle VectorGeneChem, ChinaN/AParent adenoviral shuttle vector used for reporter plasmid construction.
qPCR SystemApplied Biosystems, USAQuantStudio 5Real-time PCR system used for quantitative gene expression analysis.
Restriction Enzymes (BamHI and KpnI)Abclonal, ChinaRK21101, RK21104Restriction enzymes used for shuttle-vector linearization.
Reverse Transcription KitTransGen Biotech, ChinaAT311Reverse-transcription kit used for cDNA synthesis before RT-qPCR.
RNA Lysis ReagentInvitrogen, USA15596026Reagent used for total RNA extraction from cultured cells.
SB431542MedChemExpress, China301836-41-9TGF-β type I receptor inhibitor used for pharmacological inhibition experiments.
Sanger Sequencing Service/ReagentsShanghai Boshang Biotechnology Co., Ltd., ChinaCustom ServiceSequencing service/reagents used for plasmid sequence verification.
Serological PipettesCorning, USA4488Sterile pipettes used for liquid handling during cell culture procedures.
T30 Thermal CyclerLongGene Scientific Instruments, ChinaT30Thermal cycler used for reverse transcription and PCR amplification.
Trypsin-EDTA SolutionGibco, USA25200-056Cell dissociation reagent used for routine cell passaging.
Viral Purification KitTakara Bio USA631533Kit used for recombinant adenovirus purification.
Water BathShanghai Yiheng Scientific Instruments,ChinaHWS-12Temperature-controlled water bath used during adenoviral freeze–thaw cycles.

References

  1. Frangogiannis NG. Cardiac fibrosis. Cardiovasc Res. 2021;117(6):1450–1488.
  2. Ghazal R, et al. Cardiac fibrosis in the multi-omics era: implications for heart failure. Circ Res. 2025;136(7):773–802.
  3. Kurose H. Cardiac fibrosis and fibroblasts. Cells. 2021;10(7):1716.
  4. Heidenreich PA, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Am Coll Cardiol. 2022;79(17):e263–e421.
  5. Fang L, et al. A clinical perspective of anti-fibrotic therapies for cardiovascular disease. Front Pharmacol. 2017;8:186.
  6. Khalid A, et al. Breaking new ground in heart failure management: novel therapies and future frontiers. Fr....

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Tags

Fibroblast Reporter SystemAdenoviral TransductionCardiac FibrosisTGF-Beta ModelmCherry ReporterHigh-Throughput ScreeningReverse Transcription PCRExtracellular Matrix